From Casetext: Smarter Legal Research

Enos v. Key Pharmaceuticals, Inc.

United States Court of Appeals, Eighth Circuit
Feb 10, 1997
106 F.3d 838 (8th Cir. 1997)


No. 96-1443SD

Submitted November 18, 1996

Filed February 10, 1997

Counsel who presented argument on behalf of the appellant was Thomas H. Fain of Seattle, WA.

Counsel who presented argument on behalf of the appellee Key Pharmaceuticals was Glen H. Johnson of Rapid City, SD. William P. Studer of St. Paul, MN argued for Pfizer Inc.

Appeal from the United States District Court for the District of South Dakota.

Before FAGG, LAY, and HANSEN, Circuit Judges.

When he was three years old, Jason Enos was taking an asthma medication called theophylline. Jason suffered seizures and severe brain damage. In 1983, his mother Cheryl sued Jason's doctors for malpractice. Jason's attorneys asked Dr. Miles Weinberger, a theophylline authority, for his opinion on the cause of Jason's seizures. Dr. Weinberger found fault with Jason's doctors, but said the seizures probably were not caused by theophylline. The parties settled. In exchange for $900,000, both Cheryl and Jason's father David Enos signed a broadly worded release. In 1995, David Enos brought this action on Jason's behalf against Key Pharmaceuticals, Inc., and Pfizer, Inc., producers of theophylline under the respective brand names Theo-Dur and Sustaire. David's claims include products liability, fraud, and misrepresentation. Key and Pfizer moved for summary judgment, asserting in defense the release David signed. The district court granted the motion, David appeals, and we affirm.

We review de novo the district court's grant of summary judgment, applying the same standards as did the district court. See PMX Indus., Inc. v. LEP Profit Int'l, 31 F.3d 701, 703 (8th Cir. 1994). South Dakota law controls this diversity case, and we review the district court's interpretation of that law de novo. See Salve Regina College v. Russell, 499 U.S. 225, 231 (1991).

The district court concluded the release Jason's parents executed was general and hence bars David's present claims. We agree. In South Dakota as elsewhere, a release is a contract. See Johnson v. Rapid City Softball Ass'n, 514 N.W.2d 693, 697 (S.D. 1994). In construing a contract, courts must give effect to the intent of the parties, which is found in the contract's language. See American State Bank v. Adkins, 458 N.W.2d 807, 809 (S.D. 1990). The instrument Cheryl and David signed released both Jason's doctors and all other persons, firms, corporations, or entities who are or might be liable, . . . from any and all actions, causes of action, claims, demands, damages . . . of every kind, character and description, including, but not limited to, such allegedly on account of, or in any way growing out of, . . . personal injuries and property damage . . . resulting, or to result, from the alleged negligence and malpractice of Defendants . . . or others.

David mistakenly construes the quoted language as releasing only claims resulting from negligence and malpractice, not the products liability and other claims David now asserts. The plain terms of the release contradict David's interpretation. The contract releases all entities from all claims of every kind, "including, but not limited to" claims resulting from negligence and malpractice. David signed a general release. See Flynn v. Lockhart, 526 N.W.2d 743, 744-46 (S.D. 1995); Cleland v. United States, 874 F.2d 517, 519 (8th Cir. 1989).

Anticipating our conclusion, David contends that even if the release was general, South Dakota public policy forbids our enforcing it in Key's and Pfizer's favor. David cites South Dakota Codified Laws Section(s) 53-9-3 (Michie 1990), which provides:

All contracts which have for their object, directly or indirectly, to exempt anyone from responsibility for his own fraud or willful injury to the person or property of another . . . are against the policy of the law.

The district court concluded Section(s) 53-9-3 applies only to the parties to a contract, not to nonparties like Key or Pfizer. In dicta, the Supreme Court of South Dakota has gone a little further than that, suggesting Section(s) 53-9-3 would apply against a nonparty who was a fiduciary of a party to a release. See Rosebud Sioux Tribe v. Strain, 432 N.W.2d 259, 263 n. 2 (S.D. 1988). But neither Key nor Pfizer was Jason's or David's fiduciary. Indeed, contrary to David's view, the public policy of South Dakota favors assertion of release by nonparties to the release contract. See Flynn, 526 N.W.2d at 745-46.

Finally, David argues Key and Pfizer should be equitably estopped from relying on the release because Dr. Weinberger concealed material facts from Jason's attorneys. See Century 21 Associated Realty v. Hoffman, 503 N.W.2d 861, 866 (S.D. 1993) (listing elements of equitable estoppel). For equitable estoppel to apply against Key and Pfizer, Jason must have been deceived by Key and Pfizer. See id. Thus, Dr. Weinberger's conduct is irrelevant unless in his dealings with Jason's attorneys, the doctor acted as Key's and Pfizer's agent. Although David contends Dr. Weinberger had a financial interest in Key, David has not asserted facts that, taken as true, would establish the doctor was Key's agent. See Southard v. Hansen, 376 N.W.2d 56, 58 (S.D. 1985) (reciting elements of agency relationship).

We sympathize with Jason, but the law in this case is clear. Jason's parents agreed to release all claims. We thus affirm the judgment of the district court.

Summaries of

Enos v. Key Pharmaceuticals, Inc.

United States Court of Appeals, Eighth Circuit
Feb 10, 1997
106 F.3d 838 (8th Cir. 1997)
Case details for

Enos v. Key Pharmaceuticals, Inc.

Case Details

Full title:David Enos, general guardian and parent of Jason Enos, a minor, Appellant…

Court:United States Court of Appeals, Eighth Circuit

Date published: Feb 10, 1997


106 F.3d 838 (8th Cir. 1997)

Citing Cases

State of Minnesota v. Apfel

The power to alter the terms of section 418 agreements lies exclusively with Congress. Because Congress has…

Kunferman v. Ford Motor Company

II. DISCUSSION We review a grant of summary judgment de novo, applying the same standards as the district…